Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Pasquini

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Cells|February 15, 2022
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation InhibitionAlessandro Papa, Silvia Pasquini, Chiara Contri, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2018
Development of novel pyridazinone-based adenosine receptor ligandsDaniela Catarzi, Flavia Varano, Matteo Falsini, et al.
European Journal of Medicinal Chemistry|June 18, 2018
Structure-activity relationship studies and pharmacological characterization of N<sup>5</sup>-heteroarylalkyl-substituted-2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivatives as inverse agonists at human A<sub>2A</sub> adenosine receptorFlavia Varano, Daniela Catarzi, Fabrizio Vincenzi, et al.
Cells|April 30, 2020
Adenosinergic System Involvement in Ischemic Stroke Patients' LymphocytesSilvia Pasquini, Fabrizio Vincenzi, Ilaria Casetta, et al.
Pharmaceuticals (Basel, Switzerland)|October 27, 2019
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A<sub>1</sub>/A<sub>2B</sub> Partial AgonistsDaniela Catarzi, Flavia Varano, Katia Varani, et al.
International Journal of Molecular Sciences|May 14, 2022
A<sub>2A</sub> Adenosine Receptor: A Possible Therapeutic Target for Alzheimer's Disease by Regulating NLRP3 Inflammasome Activity?Stefania Merighi, Manuela Nigro, Alessia Travagli, et al.
Molecular Diagnosis & Therapy|March 11, 2026
Colorectal Cancer: A Landscape of New Potential RadiopharmaceuticalsVeronica Serena Cabitza, Pier Cesare Capponi, Irene Brusa, et al.
Cells|September 28, 2021
A<sub>2A</sub> Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer's DiseaseStefania Gessi, Tino Emanuele Poloni, Giulia Negro, et al.
Journal of Cellular Physiology|September 18, 2016
Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial CellsFabrizio Vincenzi, Annalisa Ravani, Silvia Pasquini, et al.
Pharmaceutics|October 28, 2023
Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases TherapyMercedes Fernandez, Manuela Nigro, Alessia Travagli, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Cells|February 15, 2022
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation InhibitionAlessandro Papa, Silvia Pasquini, Chiara Contri, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2018
Development of novel pyridazinone-based adenosine receptor ligandsDaniela Catarzi, Flavia Varano, Matteo Falsini, et al.
European Journal of Medicinal Chemistry|June 18, 2018
Structure-activity relationship studies and pharmacological characterization of N<sup>5</sup>-heteroarylalkyl-substituted-2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivatives as inverse agonists at human A<sub>2A</sub> adenosine receptorFlavia Varano, Daniela Catarzi, Fabrizio Vincenzi, et al.
Cells|April 30, 2020
Adenosinergic System Involvement in Ischemic Stroke Patients' LymphocytesSilvia Pasquini, Fabrizio Vincenzi, Ilaria Casetta, et al.
Pharmaceuticals (Basel, Switzerland)|October 27, 2019
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A<sub>1</sub>/A<sub>2B</sub> Partial AgonistsDaniela Catarzi, Flavia Varano, Katia Varani, et al.
International Journal of Molecular Sciences|May 14, 2022
A<sub>2A</sub> Adenosine Receptor: A Possible Therapeutic Target for Alzheimer's Disease by Regulating NLRP3 Inflammasome Activity?Stefania Merighi, Manuela Nigro, Alessia Travagli, et al.
Molecular Diagnosis & Therapy|March 11, 2026
Colorectal Cancer: A Landscape of New Potential RadiopharmaceuticalsVeronica Serena Cabitza, Pier Cesare Capponi, Irene Brusa, et al.
Cells|September 28, 2021
A<sub>2A</sub> Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer's DiseaseStefania Gessi, Tino Emanuele Poloni, Giulia Negro, et al.
Journal of Cellular Physiology|September 18, 2016
Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial CellsFabrizio Vincenzi, Annalisa Ravani, Silvia Pasquini, et al.
Pharmaceutics|October 28, 2023
Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases TherapyMercedes Fernandez, Manuela Nigro, Alessia Travagli, et al.
Pageof 5